RU2018138837A - Т-клеточные рецепторы - Google Patents

Т-клеточные рецепторы Download PDF

Info

Publication number
RU2018138837A
RU2018138837A RU2018138837A RU2018138837A RU2018138837A RU 2018138837 A RU2018138837 A RU 2018138837A RU 2018138837 A RU2018138837 A RU 2018138837A RU 2018138837 A RU2018138837 A RU 2018138837A RU 2018138837 A RU2018138837 A RU 2018138837A
Authority
RU
Russia
Prior art keywords
amino acid
acid residues
sequence
tcr
seq
Prior art date
Application number
RU2018138837A
Other languages
English (en)
Russian (ru)
Other versions
RU2018138837A3 (https=
Inventor
Николас ТРИББЛ
Уильям ЛОУРЕНС
Элинор БЭГГ
Original Assignee
Адаптимьюн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58536983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018138837(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Адаптимьюн Лимитед filed Critical Адаптимьюн Лимитед
Publication of RU2018138837A publication Critical patent/RU2018138837A/ru
Publication of RU2018138837A3 publication Critical patent/RU2018138837A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2018138837A 2016-04-08 2017-04-10 Т-клеточные рецепторы RU2018138837A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1606156.6 2016-04-08
GB201606156 2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (2)

Publication Number Publication Date
RU2018138837A true RU2018138837A (ru) 2020-05-12
RU2018138837A3 RU2018138837A3 (https=) 2020-07-30

Family

ID=58536983

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018138837A RU2018138837A (ru) 2016-04-08 2017-04-10 Т-клеточные рецепторы

Country Status (15)

Country Link
US (3) US20190144521A1 (https=)
EP (2) EP3925972A1 (https=)
JP (2) JP7204484B2 (https=)
KR (1) KR20190065189A (https=)
CN (2) CN116239669A (https=)
AU (2) AU2017248121B2 (https=)
BR (1) BR112018070637A2 (https=)
CA (1) CA3020555A1 (https=)
ES (1) ES2788188T5 (https=)
IL (1) IL262124A (https=)
MX (1) MX389173B (https=)
RU (1) RU2018138837A (https=)
SG (1) SG11201808750PA (https=)
WO (1) WO2017174823A1 (https=)
ZA (1) ZA201806862B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (fr) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
DK3440106T3 (da) 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
KR20190059874A (ko) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
BR112018070637A2 (pt) 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
EP3747456A4 (en) * 2018-01-31 2021-12-01 Tohoku University PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
AU2020327671A1 (en) 2019-08-13 2022-03-03 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the IL-1 superfamily
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CA3183756A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021410689A1 (en) * 2020-12-22 2023-07-06 Amgen Inc. Mage-b2-specific t-cell receptors
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
WO2025021979A1 (en) * 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
CN121358777A (zh) * 2023-07-27 2026-01-16 伊玛提克斯生物技术有限公司 抗mageb2的抗原结合蛋白
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US20120009162A1 (en) * 2009-04-03 2012-01-12 Masaki Yasukawa T cell receptor and nucleic acid encoding the receptor
ES2533228T3 (es) 2009-06-09 2015-04-08 Vaxon Biotech Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
SG11201400521PA (en) * 2011-10-14 2014-08-28 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d
CA3051222C (en) * 2013-06-10 2023-01-24 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
JP6255360B2 (ja) 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
KR20190059874A (ko) 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
BR112018070637A2 (pt) 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
SMT202200306T1 (it) 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
DK3440106T3 (da) 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer

Also Published As

Publication number Publication date
CN116239669A (zh) 2023-06-09
US20240010702A1 (en) 2024-01-11
ES2788188T3 (es) 2020-10-20
IL262124A (en) 2018-11-29
JP7572399B2 (ja) 2024-10-23
BR112018070637A2 (pt) 2019-02-05
US11753456B2 (en) 2023-09-12
CA3020555A1 (en) 2017-10-12
ES2788188T5 (es) 2023-10-24
WO2017174823A1 (en) 2017-10-12
JP7204484B2 (ja) 2023-01-16
ZA201806862B (en) 2021-04-28
KR20190065189A (ko) 2019-06-11
AU2017248121B2 (en) 2022-07-21
US20190144521A1 (en) 2019-05-16
JP2019516356A (ja) 2019-06-20
MX389173B (es) 2025-03-20
AU2022256182A1 (en) 2022-11-24
CN109476724A (zh) 2019-03-15
RU2018138837A3 (https=) 2020-07-30
SG11201808750PA (en) 2018-11-29
MX2018012268A (es) 2019-02-07
NZ747962A (en) 2024-12-20
EP3440104B2 (en) 2023-06-14
JP2022122913A (ja) 2022-08-23
AU2017248121A1 (en) 2018-11-22
EP3440104B1 (en) 2020-03-11
WO2017174823A4 (en) 2017-12-07
CN109476724B (zh) 2023-04-04
EP3440104A1 (en) 2019-02-13
EP3925972A1 (en) 2021-12-22
US20220025013A1 (en) 2022-01-27
US12180261B2 (en) 2024-12-31

Similar Documents

Publication Publication Date Title
RU2018138837A (ru) Т-клеточные рецепторы
RU2018138838A (ru) Т-клеточные рецепторы
RU2018138836A (ru) Т-клеточные рецепторы
ES2985686T3 (es) Receptores de células T
HRP20220865T1 (hr) T stanični receptori
ES2912743T3 (es) Receptores de linfocitos T
CN109476723B (zh) Ny-eso-1肿瘤抗原hla-a*02复合物的特异性t细胞受体
JP2017533698A5 (https=)
JP2020127406A5 (https=)
FI3433270T3 (fi) T-solureseptoreita
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
JP7483746B2 (ja) Ｍａｇｅａ１特異的ｔ細胞受容体およびその使用
CN115052885A (zh) 特异性结合分子
JP2023522799A5 (https=)
JP2023532760A (ja) 特異的結合分子
IL314832A (en) Hiv-specific binding molecules and tcr
Croft et al. Peptidomimetics: modifying peptides in the pursuit of better vaccines
CN113874393B (zh) 对hbv包膜蛋白具有特异性的结合分子
NZ747962B2 (en) T cell receptors
NZ747974B2 (en) T cell receptors
NZ747982B2 (en) T cell receptors
CN118715240A (zh) Hiv特异性结合分子和tcr
RU2022116808A (ru) Т-клеточные рецепторы